Apyx Medical Intrinsic Stock Value – APYX MEDICAL Reports 31.9% Increase in Revenue for Q2 FY2023: USD 13.6 Million
August 12, 2023
☀️Earnings Overview
APYX MEDICAL ($NASDAQ:APYX) reported their financial results for the second quarter of FY2023 on June 30 2023, with total revenue of USD 13.6 million – an increase of 31.9% from the same quarter in the prior year. Net income for the quarter was USD -0.99 million, compared to -5.43 million in the year before.
Analysis – Apyx Medical Intrinsic Stock Value
GoodWhale has conducted a comprehensive analysis of the wellbeing of APYX MEDICAL, and the results have shown that the fair value of APYX MEDICAL share should be around $8.5, which is calculated by our proprietary Valuation Line. Currently, APYX MEDICAL stock is traded at $4.2, which means it is undervalued by 50.8%. This presents an opportunity for investors to receive an attractive return on their investment by purchasing APYX MEDICAL shares. We believe that APYX MEDICAL is well-positioned to capitalize on the current market trend and grow its business in the near future. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Apyx Medical. More…
| Total Revenues | Net Income | Net Margin |
| 47.44 | -16.29 | -39.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Apyx Medical. More…
| Operations | Investing | Financing |
| -16.62 | 6.67 | 8.28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Apyx Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 62.43 | 25.7 | 1.06 |
Key Ratios Snapshot
Some of the financial key ratios for Apyx Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 23.4% | – | -37.2% |
| FCF Margin | ROE | ROA |
| -36.3% | -30.3% | -17.7% |
Peers
The medical device industry is highly competitive, with Apyx Medical Corp competing against Therma Bright Inc, NeuroOne Medical Technologies Corp, and Brain Scientific Inc. All four companies are vying for a share of the market, with each company offering a unique product or service.
– Therma Bright Inc ($TSXV:THRM)
Therma Bright Inc is a medical device company that develops, manufactures, and markets LED-based therapies. Its products are used for the treatment of acne, psoriasis, and other skin conditions. The company has a market cap of 31.14M as of 2022 and a return on equity of -263.61%.
– NeuroOne Medical Technologies Corp ($NASDAQ:NMTC)
NeuroOne Medical Technologies Corp is a medical device company that develops and commercializes electrode technologies for the treatment of neurological disorders. The company has a market cap of 15.89M and a ROE of -59.33%. The company’s electrode technologies are based on a thin-film platform that is designed to provide superior performance and patient outcomes. The company’s products are used in a variety of neurosurgical procedures, including deep brain stimulation, epilepsy surgery, and neurostimulation.
– Brain Scientific Inc ($OTCPK:BRSF)
NeuroScientific Inc is a biotechnology company that focuses on the development and commercialization of drugs for the treatment of neurological disorders. The company has a market cap of 12.24M as of 2022 and a return on equity of 632.23%. NeuroScientific’s products are designed to target specific areas of the brain, which the company believes will lead to more effective treatments for neurological disorders. The company’s products are in various stages of development, and it has partnered with several major pharmaceutical companies to commercialize its products.
Summary
Investors should take note that APYX MEDICAL reported their financial results for the second quarter of FY 2023, showing total revenue of USD 13.6 million – a 31.9% increase year-over-year. Despite the increase in revenue, net income for the quarter was USD -0.99 million, a decrease from the prior year’s -5.43 million. As a result, the stock price moved down the same day. Investors should take a closer look at APYX MEDICAL to understand if the company is worth investing in despite the weak financials.
Related Posts
Recent Posts
